Fig. 6: The expression of ESRP1 is substantially elevated in breast carcinoma-in-situ compared to normal breast tissue. | Oncogenesis

Fig. 6: The expression of ESRP1 is substantially elevated in breast carcinoma-in-situ compared to normal breast tissue.

From: E2F1 and epigenetic modifiers orchestrate breast cancer progression by regulating oxygen-dependent ESRP1 expression

Fig. 6

The elevated levels of transcriptional activator E2F1 and gain of 5hmC marks on the ESRP1 promoter govern the ESRP1 upregulation. However, ESRP1 expression is severely diminished within the hypoxic tumor niche despite a high E2F1 level. Mechanistically, hypoxia-driven reduction in TET3 activity coerces the E2F1 binding site on the ESRP1 promoter to lose 5hmC marks while gaining DNMT3A/3B-dependent 5mC marks. Additionally, elevated E2F1 regulates the hypoxia-specific spliceome by inducing SRSF7 expression.

Back to article page